Neuro,
You really need to listen to the audio, because MV made what I consider a somewhat strange statement. He said the
"final trial design" had not been completed yet, and CORX was discussing with potential partners the design of the trial. Why would CORX need the imprimatur of a potential partner on the trial design? Won't the design of the ADHD trial with 1739 follow the exact same design of the very succesful design of the trial protocols followed in the CX1737 trial?
I found the statement a bit unusual, so I'll throw something out that is completely and utterly off-the-wall: Maybe the design of the trial has been held up because Valeant/Biovail management needs to sign off on the design. And maybe the Valeant/Biovail deal has slowed things down. Maybe the RD deal with Biovail was really an option on (the rest of) CX1739. (MV said that CORX did NOT have the rights to RD with CX1739. Who does? I didn't realize that the rights to RD with 1739 were part of the Biovail deal. Or did CORX simply promise Biovail that it wouldn't develop 1739 in that particular indication? If Biovail already has the rights to 1739 for RD, then it would make sense that Valeant/Biovail is the most likely partner for 1739 in ADHD--CORX doesn't want to split the rights to a single molecule (They tried that once before and it was a disaster.), so Biovail is the obvious first choice for a partnership in ADHD. I admit that this is just crazy speculation.
The other problem I had with the presentation is that MV presented the molecules partnered with MRK as if they were still in development. That seems to be disingenuous, at best.
(You can hear MV's remarks on the ADHD trial--he says it twice,explicitly at the 12:42 and 20:44 mark of the presentation that the IND has not been submitted.)
Bladerunner
News 
Market Data 
Discover 
